Unlock instant, AI-driven research and patent intelligence for your innovation.

Quaternary ammonium salt of penehyclidine optical isomer, medicinal composition and medical application thereof

A technology of optical isomers and penehyclidine, which is applied in the field of selective M3 receptor antagonists, salts or solvates, can solve problems such as the inability to predict whether the isomer is effective or ineffective

Inactive Publication Date: 2011-05-25
INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
View PDF5 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Based on current knowledge in the art, it is impossible to predict which isomer will be effective or ineffective; nor can it be asserted that one of the optical isomers will necessarily have better biological properties than the racemate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quaternary ammonium salt of penehyclidine optical isomer, medicinal composition and medical application thereof
  • Quaternary ammonium salt of penehyclidine optical isomer, medicinal composition and medical application thereof
  • Quaternary ammonium salt of penehyclidine optical isomer, medicinal composition and medical application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Embodiment 1, Preparation of (R)-α-phenyl-α-cyclopentyl-1,2-oxirane (IX)

[0076] 1.1、 Preparation of (2R,5R)-2-tert-butyl-5-phenyl-1,3-dioxan-4-one (II)

[0077] Add 20 g (0.13 mol) of R-mandelic acid in 200 mL of n-pentane, then add 21.2 mL of pivalaldehyde (content 80%, 0.16 mol, purchased from Fluka Company), and then add 0.5 mL of trifluoromethanesulfonic acid to make the The mixture was refluxed for 6 hours. Remove the generated water with a water separator. Cool to room temperature, add 100 mL of 8% sodium bicarbonate solution, distill under reduced pressure, remove n-pentane, and filter to obtain (2R,5R)-2-tert-butyl-5-phenyl-1,3-dioxane- 4-ketone (II), yield 27.1g, melting point 100-102°C, yield 95%, elemental analysis, theoretical value %: C 70.89, H 7.32; experimental value %: C 70.81, H 7.39. 1 H-NMR, δ (ppm, CDCl 3 ): 1.10(s, 9H), 5.25(s, 1H), 5.38(s, 1H), 7.47(m, 5H).

[0078] 1.2、 Preparation of (2R,5S)-2-tert-butyl-5-phenyl-5-(cyclopentyl-1-hydr...

Embodiment 2

[0089] Embodiment 2, Preparation of 3-(R)-[2'-(R)-2'-hydroxy-2'-cyclopentyl-2'-phenylethoxy]-quinuclidane (X)

[0090] Under the protection of nitrogen, put 0.6g (15mmol) of NaH in a dry three-necked flask, add 10mL of anhydrous DMSO, after stirring for 5min, dropwise add 1.8g (14.2mmol) of 3-(R)-quinuclidinol ) in 10 mL DMSO, and the reaction was stirred at 60 °C for 1 h. After cooling to room temperature, a solution of (R)-α-phenyl-α-cyclopentyl-1,2-oxirane (IX) 2.61 g (14 mmol) in 10 mL of DMSO was slowly added dropwise. The reaction was stirred at 50 °C for 3 h, cooled, and 20 mL of water was carefully added dropwise. Extract with ether, wash with water, wash the ether layer with 10% hydrochloric acid solution, combine the water phases; basify the obtained hydrochloric acid extract with 40% NaOH, extract with ether, dry with anhydrous sodium sulfate, distill, remove the solvent, The colorless liquid of X was obtained, 2.84g, yield 65%, (MeOH, c=0.35). 1 H NMR, δ (pp...

Embodiment 3

[0091] Embodiment 3, N-methyl-3-(R)-[2′-(R)-2′-hydroxy-2′-cyclopentyl-2′-phenylethoxy]-quinuclidinyl bromide (I 1 ) preparation

[0092] Dissolve 3.15g (10mmol) of X in 20ml of acetone, add 1.04g (11mmol) of methyl bromide and stir, react at 50-60°C for 3-10 hours, spot the plate until the raw material point disappears, stop the reaction, cool down to 10-20°C, slowly Slowly add anhydrous diethyl ether dropwise until no solid precipitates out, filter with suction, and dry in vacuo to give I 1 3.89g, yield 95%, (EtOH, c=0.01). 1 H-NMR, δ (ppm, D 2 O): 7.32(m, 2H), 7.21(m, 2H), 7.11(m, 1H), 4.28(m, 1H), 3.79(d, 1H), 3.71(br t, 1H), 3.46(d, 1H), 3.38(m, 1H), 3.11(m, 1H), 2.99(m, 2H), 2.84(m, 2H), 2.65(s, 3H), 2.24(m, 1H), 2.16(br, 1H ), 1.80 (m, 1H), 1.20-1.61 (m, 9H), 0.94-1.09 (m, 2H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
optical purityaaaaaaaaaa
Login to View More

Abstract

The invention relates to a quaternary ammonium salt compound shown as a formula I, or pharmaceutically acceptable salt or solvate thereof. The invention also relates to application of the compound as a selective M receptor antagonist, particularly a selective M3 receptor antagonist, and a compound-containing medicinal composition.

Description

Technical field: [0001] The present invention relates to a quaternary ammonium salt compound represented by formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to said compounds as selective M receptor antagonists, especially selective M 3 Use of receptor antagonists, and pharmaceutical compositions comprising said compounds. [0002] Background technique: [0003] M-choline receptors are very important targets for drug therapy. M-receptor antagonist anticholinergics have bronchiectasis, secretion inhibition and lower vagus nerve tone, which can effectively treat chronic obstructive pulmonary disease; by inhibiting the secretion of respiratory glands, they can effectively relieve the symptoms of runny nose and nasal congestion of colds; M Receptor antagonists can also reduce respiratory secretion and keep the airway open, and are often used as premedication before inhalation anesthesia. Therefore, the development of therapeut...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D453/02A61K31/439A61P11/00A61P31/16A61P43/00
Inventor 仲伯华郑建全何新华李昕王丽韫刘河刘克良
Owner INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A